Durvalumab, Gemcitabine And Cisplatin Continue To Show Clinically Meaningful Long-Term Survival ...

Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival ...

Nivolumab plus gemcitabine-cisplatin shows benefit for locally advanced mUC

The NIAGARA Trial, Cisplatin Regimens, and the Potential of Durvalumab With Gem/Cis for MIBC

GU Oncology Now

HRQoL in KEYNOTE-966: pembrolizumab with gemcitabine and cisplatin for advanced biliary tract cancer

CheckMate 901: nivolumab with gemcitabine-cisplatin in urothelial carcinoma

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of MIBC patients

Gemcitabine, Cisplatin, and Nab-paclitaxel in Advanced Biliary Tract Cancer

Nivolumab + Gemcitabine-Cisplatin vs. Gemcitabine-Cisplatin in Metastatic Urothelial Cancer | CRSF

CRSF - Cancer Research and Statistic Foundation

KEYNOTE-966: pembrolizumab, gemcitabine and cisplatin for CCA

SWOG 1815: gemcitabine, cisplatin, and nab-paclitaxel in biliary tract cancer

Gemcitabine, cisplatin, and nab-paclitaxel in advanced biliary tract cancers

Addressing the impact of neoadjuvant treatment for MIBC in the NIAGARA trial

Webinar: Combination of Durvalumab, Bevacizumab, Tremelimumab & Transarterial Chemoembolization

Cholangiocarcinoma Foundation

ABC-07 : chemotherapy with or without SBRT in cholangiocarcinoma

Adjuvant Pembrolizumab, Durvalumab, and More Considerations From UC Trials Presented at ESMO 2024

GU Oncology Now

Dr. Gupta on the Use of Enzalutamide, Gemcitabine, and Cisplatin in Metastatic Bladder Cancer

HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder s...

Cisplatin-Based Therapy in Muscle-Invasive Bladder Cancer

Neoadjuvant Cisplatin-Based Chemotherapy for Muscle Invasive Bladder Cancer

Grand Rounds in Urology